The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
 
David M. O'Malley
Consulting or Advisory Role - Adaptimmune; Agenus; Arcus Biosciences; AstraZeneca; Atossa Therapeutics; BBI Healthcare; Celsion; Clovis Oncology; Corcept Therapeutics; DualityBio; Eisai; Elevar Therapeutics; Genelux; Genentech/Roche; GlaxoSmithKline; GOG Foundation; Immunogen; Imvax; InxMed; Jazz Pharmaceuticals; Laekna Therapeutics; Merck; Mersana; Novartis; Novocure; Novocure; OncoC4; Onconova Therapeutics; Regeneron; Roche; Seagen; Sutro Biopharma; Takeda; Toray Industries; Umoja Biopharma; VBL Therapeutics; Verastem; Vincerx Pharma
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); TRACON Pharma (Inst); Verastem (Inst)
 
Tashanna K. N. Myers
Consulting or Advisory Role - Immunogen; Immunogen
 
Claudio Zamagni
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daichi-Sankyo; EISAI; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche; Seagen
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Medivation (Inst); Morphotek (Inst); Novartis (Inst); pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichi-Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Elisabeth Diver
Consulting or Advisory Role - EMD Serono; GlaxoSmithKline; Novartis
Research Funding - Aravive (Inst); EMD Serono/Merck (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Tempus
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genmab; GlaxoSmithKline; ImmunoGen; MSD; PharmaMar; Seagen
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup